Xanthine compounds
CA 2045478 C · Owner: Grupo Plafin, S.A. · Inventors: Gristwood, Robert W.; Noverola, Armando V.; Soto, Jose M. P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Xanthines of general formula (I), wherein R1 represents a straight or branched chain alkyl alkenyl or alkynyl group of, 3-6 carbon atoms and R2 and R3, which may be the same or different each represent hydrogen or halogen or a methyl methoxy. nitro or trifluoromethyl group or R2 and R3 together form a methylenedioxy or ethylenedioxy group; with the proviso that R2 and R3 are not both hydrogen; and pharmacologically acceptable salts thereof with an alkali metal base or a nitrogen base containing organic base, are bronchodilators making them of value in treating asthma and vasodilators making them of interest in treating angina, hypertension congestive heart failure and multi-infarct …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 27, 1990 and granted December 29, 1998. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.